Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Chapter 34 - Dopamine replacement for Parkinson's disease: Clinical approaches and experimental underpinnings

Cenci, M. Angela LU orcid ; Rosqvist, Kristina LU and Odin, Per LU orcid (2025) 32. p.447-457
Abstract
Parkinson's disease (PD) is characterized by a set of motor symptoms that depend on nigrostriatal dopaminergic degeneration and respond well to pharmacological dopamine replacement using L-DOPA. However, replacing dopamine with either L-DOPA or dopamine receptor agonists leads to the appearance of motor and nonmotor complications within a few years. Strong emphasis is currently placed on developing strategies for continuous drug delivery that can reduce fluctuations in motor and nonmotor states associated with standard oral therapy. Here, we summarize both currently available treatments and those that are in an advanced phase of clinical development. We then review key experimental findings elucidating how different treatment approaches... (More)
Parkinson's disease (PD) is characterized by a set of motor symptoms that depend on nigrostriatal dopaminergic degeneration and respond well to pharmacological dopamine replacement using L-DOPA. However, replacing dopamine with either L-DOPA or dopamine receptor agonists leads to the appearance of motor and nonmotor complications within a few years. Strong emphasis is currently placed on developing strategies for continuous drug delivery that can reduce fluctuations in motor and nonmotor states associated with standard oral therapy. Here, we summarize both currently available treatments and those that are in an advanced phase of clinical development. We then review key experimental findings elucidating how different treatment approaches affect dopamine-dependent signaling and behavior. We moreover discuss the fundamentally important and still open question of how dopamine replacement is to be achieved in order to maximize therapeutic efficacy and minimize the risk of debilitating complications. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
keywords
Dyskinesia, Movement disorders, Basal ganglia, Striatum, Neurotransmitter, Therapeutics
host publication
The Handbook of Dopamine
editor
Cragg, Stephanie J. and Walton, Mark E.
volume
32
pages
447 - 457
publisher
Elsevier
external identifiers
  • scopus:105012183093
DOI
10.1016/B978-0-443-29867-7.00040-2
language
English
LU publication?
yes
id
d0fb3717-f383-412f-8479-f3166143da50
alternative location
https://www.sciencedirect.com/science/article/pii/B9780443298677000402
date added to LUP
2025-12-01 15:05:03
date last changed
2025-12-02 08:35:47
@inbook{d0fb3717-f383-412f-8479-f3166143da50,
  abstract     = {{Parkinson's disease (PD) is characterized by a set of motor symptoms that depend on nigrostriatal dopaminergic degeneration and respond well to pharmacological dopamine replacement using L-DOPA. However, replacing dopamine with either L-DOPA or dopamine receptor agonists leads to the appearance of motor and nonmotor complications within a few years. Strong emphasis is currently placed on developing strategies for continuous drug delivery that can reduce fluctuations in motor and nonmotor states associated with standard oral therapy. Here, we summarize both currently available treatments and those that are in an advanced phase of clinical development. We then review key experimental findings elucidating how different treatment approaches affect dopamine-dependent signaling and behavior. We moreover discuss the fundamentally important and still open question of how dopamine replacement is to be achieved in order to maximize therapeutic efficacy and minimize the risk of debilitating complications.}},
  author       = {{Cenci, M. Angela and Rosqvist, Kristina and Odin, Per}},
  booktitle    = {{The Handbook of Dopamine}},
  editor       = {{Cragg, Stephanie J. and Walton, Mark E.}},
  keywords     = {{Dyskinesia; Movement disorders; Basal ganglia; Striatum; Neurotransmitter; Therapeutics}},
  language     = {{eng}},
  pages        = {{447--457}},
  publisher    = {{Elsevier}},
  title        = {{Chapter 34 - Dopamine replacement for Parkinson's disease: Clinical approaches and experimental underpinnings}},
  url          = {{http://dx.doi.org/10.1016/B978-0-443-29867-7.00040-2}},
  doi          = {{10.1016/B978-0-443-29867-7.00040-2}},
  volume       = {{32}},
  year         = {{2025}},
}